2679 post menopausal women with osteoporosis were randomly assigned to receive either an injection of a parathyroid hormone (PTH), or a placebo, to examine the safety and efficacy of a PTH injection. The results at 18 months, indicated that PTH was successful in reducing the risk for first fracture in those who had no prevalent fracture, as well as reducing additional fracture risk in women who had prevalent fractures. However, the findings of this study also indicated that those treated with PTH had increased hypercalciuria, hypercalcemia, and nausea, compared to the placebo group.